Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Synairgen plc

Healthcare GB SNG

NoneGBX
0.00(0%)

Last update at 2025-05-07T16:00:09.713409Z

Day Range

--
LowHigh

52 Week Range

6.0117.50
LowHigh

Fundamentals

  • Previous Close 0.95
  • Market Cap14.10M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-51.46300M
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.10M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Income before tax -20.09300M -57.85700M - -17.73200M -
Minority interest - - - - -
Net income -17.64500M -48.66300M - -13.91600M -
Selling general administrative 5.36M 5.01M - 2.25M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.10M 0.20M - 0.26M -
Ebit -20.30000M -57.86600M -17.74100M -17.74100M -4.81700M
Ebitda -19.99100M -57.66000M - -17.46200M -
Depreciation and amortization 0.31M 0.21M - 0.28M -
Non operating income net other - - - - -
Operating income -20.30000M -57.86600M - -17.74100M -
Other operating expenses 20.30M 57.87M - 17.74M -
Interest expense 0.21M 0.00200M 0.00000M 0.01000M 0.00000M
Tax provision -2.44800M -9.19400M - -3.81600M -
Interest income 0.21M 0.01M - 0.02M -
Net interest income 0.21M 0.00900M - 0.00900M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.44800M -9.19400M -3.81600M -3.81600M -0.90800M
Total revenue 0.00000M 0.00000M - 0.00000M -
Total operating expenses 20.30M 57.87M - 17.74M -
Cost of revenue - - - - -
Total other income expense net 0.21M 0.00900M - 0.00900M -
Discontinued operations - - - - -
Net income from continuing ops -17.64500M -48.66300M - -13.91600M -
Net income applicable to common shares -17.64500M -48.66300M -13.91600M -13.91600M -3.88500M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Total assets 23.53M 44.64M - 88.55M -
Intangible assets 0.04M 0.05M - 0.04M -
Earning assets - - - - -
Other current assets 0.00400M 10.59M - 13.14M -
Total liab 3.25M 7.64M - 3.41M -
Total stockholder equity 20.27M 37.00M - 85.14M -
Deferred long term liab - - - - -
Other current liab - 3.48M - 1.74M -
Common stock 2.01M 2.01M 2.00M 2.00M 1.09M
Capital stock 2.01M 2.01M - 2.00M -
Retained earnings -107.46700M -90.74100M -42.58600M -42.58600M -27.58600M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 15.93M 33.83M - 74.98M -
Cash and equivalents - - - - -
Total current liabilities 3.25M 7.64M 3.41M 3.41M 1.69M
Current deferred revenue - - - - -
Net debt -15.92600M -33.82700M - -74.84800M -
Short term debt - - - 0.13M -
Short long term debt - - - - -
Short long term debt total - - - 0.13M -
Other stockholder equity 125.73M 125.73M 0.48M 125.73M 0.48M
Property plant equipment 0.09M 0.17M 0.34M 0.34M 0.56M
Total current assets 23.40M 44.41M 88.16M 88.16M 3.50M
Long term investments - - - - -
Net tangible assets 20.23M 36.95M 85.10M 85.10M 2.24M
Short term investments 3.75M - - - -
Net receivables 1.31M 9.61M 13.14M 4.32M 1.00M
Long term debt - - - - -
Inventory - 0.00000M 0.04M 0.04M 0.04M
Accounts payable 3.25M 7.64M 3.28M 3.28M 1.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 2.00M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.13M 0.23M - 0.39M -
Capital lease obligations - 0.00000M - 0.13M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Investments -3.61600M -0.02100M - -0.04500M 0.05M
Change to liabilities -4.38400M 4.36M 1.79M 1.79M 0.71M
Total cashflows from investing activities -3.61600M -0.02100M -0.04500M -0.04500M 0.07M
Net borrowings - -0.12400M -0.19600M -0.19600M -0.19600M
Total cash from financing activities 0.00100M -0.11200M 96.39M 96.39M 96.39M
Change to operating activities - - - - -
Net income -20.09300M -57.85700M -13.91600M -17.73200M -3.88500M
Change in cash -17.90100M -41.14900M 72.52M 72.52M -2.83000M
Begin period cash flow 33.83M 74.98M 74.98M 2.45M 2.45M
End period cash flow 15.93M 33.83M 74.98M 74.98M 2.45M
Total cash from operating activities -14.28600M -41.01600M -23.81900M -23.81900M -2.89600M
Issuance of capital stock 0.00100M 0.01M - 99.78M -
Depreciation 0.10M 0.20M 0.26M 0.26M 0.16M
Other cashflows from investing activities 0.14M 0.01M 0.03M 0.03M 0.03M
Dividends paid - - - - -
Change to inventory 0.00000M 0.04M - 0.04M 0.01M
Change to account receivables 0.29M 7.84M -9.24400M -9.24400M 0.08M
Sale purchase of stock - - - - -
Other cashflows from financing activities -3.61600M -0.12600M -4.49300M -3.39800M -4.49300M
Change to netincome 7.35M -4.78900M -2.70800M -2.70800M 0.02M
Capital expenditures 0.00600M 0.03M 0.04M 0.08M 0.01000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.09500M 12.24M - -7.45500M -
Stock based compensation 0.92M 0.51M - 0.21M -
Other non cash items 8.88M -0.01300M - -0.00900M -
Free cash flow -14.29200M -41.04900M - -23.89500M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SNG
Synairgen plc		 - -% - - - 759.00 0.90 1043.09 0.32
GNS
Genus PLC		 28.00 1.29% 2198.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 2.00 1.67% 122.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 7.00 1.15% 617.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 68.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Synairgen plc

Mailpoint 810, Southampton, United Kingdom, SO16 6YD

Key Executives

Name Title Year Born
Mr. Richard Marsden CEO, MD & Exec. Director 1968
Prof. Stephen T. Holgate CBE, M.D. Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board 1948
Mr. John Ward CFO & Exec. Director 1962
Dr. Phillip David Monk Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director 1969
Prof. Donna Davies Co-Founder & Member of Scientific Advisory Board NA
Prof. Ratko Djukanovic Co-Founder & Member of Scientific Advisory Board NA
Ms. Brooke S Clarke Sr. VP & Head of Communications NA
Dr. Gareth E. Walters Ph.D. Chief Regulatory Officer 1959
Ms. Jody Brookes Sr. VP & Head of Clinical Operations NA
Mr. Richard Hennings Chief Commercial Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.